Dermatan sulphate in haemodialysis

D. A. Lane, K. Ryan, H. Ireland, J. R. Curtis, M. T. Nurmohamed, R. T. Krediet, M. C. Roggekamp, P. Stevens, J. W. ten Cate

Research output: Contribution to journalComment/Letter to the editorAcademic

Abstract

Experimental work suggests that dermatan sulphate has potential as an antithrombotic agent: it can inhibit venous thrombi yet has less effect upon bleeding than heparin. While heparin functions as an anticoagulant primarily by its ability to accelerate the action of the plasma protein inhibitor antithrombin III, dermatan sulphate acts selectively through a structurally related inhibitor, heparin co-factor II, to inhibit thrombin. We have done a series of dose-finding studies of the use of dermatan sulphate as an anticoagulant/antithrombotic agent in patients on maintenance haemodialysis. Dermatan sulphate proved to be an effective anticoagulant in this setting
Original languageEnglish
Pages (from-to)334-335
JournalLancet
Volume339
Issue number8789
DOIs
Publication statusPublished - 1992

Cite this